Ocumetics Seeks Debenture Forbearance and Warrant Incentive to Extend $4 Million Financing

An announcement from Ocumetics Technology Corp ( (TSE:OTC) ) is now available.

Ocumetics Technology Corp. has proposed a forbearance agreement with holders of its up to $4 million secured convertible debentures issued in 2024, under which debentureholders would agree not to demand repayment or enforce their security until June 19, 2027, despite the instruments reaching maturity two years from issuance. The debentures, bearing 18% annual interest and convertible into common shares at $0.32 per share, are secured by a general security agreement on the company’s personal property, and in exchange for the forbearance, Ocumetics plans—subject to TSX Venture Exchange approval—to issue new share purchase warrants to debentureholders, with each warrant exercisable at $0.58 until the earlier of June 19, 2027, or full repayment of the indebtedness. The arrangement effectively extends Ocumetics’ breathing room on its high-interest debt while offering creditors additional equity-linked upside, a move that may help support the company’s capital structure as it advances development of its ophthalmic technologies.

The most recent analyst rating on (TSE:OTC) stock is a Sell with a C$0.57 price target. To see the full list of analyst forecasts on Ocumetics Technology Corp stock, see the TSE:OTC Stock Forecast page.

Spark’s Take on TSE:OTC Stock

According to Spark, TipRanks’ AI Analyst, TSE:OTC is a Neutral.

The score is primarily held down by very weak financial performance (no revenue, ongoing losses, negative equity, and persistent cash burn). Technicals also remain bearish with the stock trading below key moving averages and negative MACD, despite oversold readings. Positive corporate updates around clinical progress and financing provide some support but are not yet reflected in operating fundamentals.

To see Spark’s full report on TSE:OTC stock, click here.

More about Ocumetics Technology Corp

Ocumetics Technology Corp. is a Canadian research and product development company focused on advanced vision correction solutions for the ophthalmic industry. It is developing state-of-the-art intraocular lenses and other vision-enhancing technologies, including a first-in-human early feasibility intraocular lens designed to sit in the eye’s natural lens compartment and potentially eliminate the need for glasses or contact lenses by allowing natural accommodation for clear vision at all distances.

Average Trading Volume: 29,086

Technical Sentiment Signal: Hold

Current Market Cap: C$137.8M

See more data about OTC stock on TipRanks’ Stock Analysis page.